Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...

Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...

Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...

CVS is trying to turn around its drugstore chain and insurance business. The company spent a smaller percentage of premium ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

For 2025, Waters expects constant currency sales growth of 4.5%-7%, translating to total reported sales growth of approximately 2.5%-5% due to FX headwinds. Non-GAAP EPS guidance is projected at ...

In a challenging market environment, shares of Eliem Therapeutics, Inc. (CLYM) have reached a 52-week low, dipping to $1.5. According to InvestingPro data, the company maintains a strong financial ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...